Recent Updates
Recently added Catalysts
BMY Positive Sentiment

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pathos AI has formed multi-year strategic collaborations with Bristol Myers Squibb and Tempus AI to enhance AI-driven drug development for Alzheimer's disease and other neurological conditions. Bristol Myers Squibb is also leading Pathos's Series E financing, gaining access to Pathos Foundry for its research and development efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pathos AI announced collaborations with BMS and Tempus AI.
  • The partnerships aim to advance AI-driven drug development.
  • BMS leads Pathos's Series E financing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+17%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
CC-95266
Phase 1 · Multiple Myeloma

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, “BMS”) and Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions. BMS also leads Pathos’s Series E financing and gains access to Pathos Foundry across its broader R&D portf

Frequently Asked Questions

What companies are collaborating with Pathos AI?

Pathos AI is collaborating with Bristol Myers Squibb and Tempus AI.

What is the focus of the collaborations?

The collaborations aim to advance AI-driven drug development for Alzheimer's disease.

Who is leading Pathos's Series E financing?

Bristol Myers Squibb is leading Pathos's Series E financing.

What will BMS gain from the collaboration?

BMS will gain access to Pathos Foundry for its broader R&D portfolio.

ShareAdd on Google
Tags: BMY Pathos AI Bristol Myers Squibb Tempus AI Alzheimer's disease neurological conditions
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$11464M liquidity · $0M/mo burn
Low dilution risk
Lead asset
CC-95266Phase 1
Multiple Myeloma →

Catalyst track record

+17%
best trade around BMY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for BMY.

See every catalyst's timing & PoA →